Sector News

Siegfried buys BASF drug ingredient businesses for $306 million

May 7, 2015
Chemical Value Chain
(Reuters) – German chemicals group BASF has agreed to sell parts of its pharmaceutical ingredients business to Swiss drug contract manufacturer Siegfried Holding for 270 million euros ($306 million), including assumed debt.
 
“Siegfried will reach the critical size to play a leading role in the supplier market as a recognized partner for the pharmaceutical industry,” said Siegfried Chief Executive Rudolf Hanko.
 
Siegfried said financing of the transaction was secured by a syndicate of Swiss banks and there were no plans for a capital increase. It plans to issue a hybrid bond for partial refinancing after completion of the deal.
 
BASF said on Thursday the move was part of a strategy to focus its pharmaceutical ingredients business on excipients, which are auxiliary pharmaceutical ingredients that help the body to better absorb a drug.
 
BASF will keep selected active ingredients such as ibuprofen, omega-3 fatty acids and polyethylene glycol (PEG), where the company has a leading market position.
 
(Reporting by Ludwig Burger; Editing by Hugh Lawson)

comments closed

Related News

September 17, 2022

Huhtamaki and Stora Enso collaborate on new paper cup recycling initiative

Chemical Value Chain

Huhtamaki and Stora Enso have joined forces to create a new paper cup recycling initiative, The Cup Collective. The programme aims to recycle and capture the value of used paper cups on an industrial scale. The programme will initially be implemented across Belgium, the Netherlands and Luxembourg.

September 17, 2022

Methanex announces new President & CEO effective January 1, 2023

Chemical Value Chain

The Board of Directors of Methanex Corporation announced that John Floren will retire as President and CEO and from the Board as of December 31, 2022. The Board has appointed Rich Sumner as President & Chief Executive Officer and member of the Board of Directors, effective January 1, 2023.

September 17, 2022

Evonik is driving growth through innovations, announces new CIO

Chemical Value Chain

Evonik’s new chief innovation officer, Ralph Marquardt, aims to strengthen the company’s innovative strength even further in the future. Marquardt, who has a doctorate in chemistry and joined Evonik in 2006, has acquired the necessary experience, for example, through leadership roles in various business areas. Sustainability is his central focus.